arrow_back Search

EFTA00872569

DOJ Epstein Files
folder Dataset 9 insert_drive_file EFTA00872569.pdf description PDF text_fields 392 words · 2.6k chars
open_in_new View original source

From: Boris Nikolic To: Jeffrey Epstein <jeeyacation@gmail.com> Subject: FW: Foundation Medicine Prices Initial Public Offering of Common Stock Date: Tue, 24 Sep 2013 22:13:42 +0000 It is priced much higher. 18 - they were thinking 12! This places valuation much higher. And just watch it will go through the roof t: Sent from my Windows Phone From: Foundation Medicine Sent: 9/24/2013 5:58 PM To: Boris Nikolic Subject: Foundation Medicine Prices Initial Public Offering of Common Stock ;`'ogr2 Sept. 24. 2013 21:50 UTC Foundation Medicine Prices Initial Public Offering of Common Stock CAMBRIDGE, Mass.—(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced the pricing of its initial public offering of 5,888,888 shares of common stock at a price of $18.00 per share, before underwriting discounts. All of the common stock is being offered by Foundation Medicine. In addition, the underwriters have a 30-day option to purchase up to an additional 883,333 shares of common stock from Foundation Medicine at the public offering price, before underwriting discounts. The company's shares are expected to begin trading on The NASDAQ Global Select Market on Wednesday, September 25, 2013 under the trading symbol "FMI." Goldman, Sachs & Co. and NI Morgan Securities, LLC acted as joint book-running managers of the offering. Leerink Swann LLC and Sanford C. Bernstein & Co., LLC acted as co-managers. A copy of the final prospectus relating to this offering may be obtained, when available, from: Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, facsimile at , or e-mail at or MI Morgan Securities LLC, do Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717. or by telephone at (866) 803-9204. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2013. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to egistration or qualification under the securities laws of any such state or jurisdiction. Contacts Media — Foundation Medicine Dan Budwick Pure Communications, Inc. Or Investors — Foundation Medicine Matt Clawson, EFTA00872569 Source: Foundation Medicine, Inc. View this news release online at: ;Powered by Business Wire EFTA00872570